Scott G Williams

Summary

Affiliation: Peter MacCallum Cancer Centre
Country: Australia

Publications

  1. ncbi Acute toxicity in prostate cancer patients treated with and without image-guided radiotherapy
    Suki Gill
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
    Radiat Oncol 6:145. 2011
  2. ncbi Expanded risk groups help determine which prostate radiotherapy sub-group may benefit from adjuvant androgen deprivation therapy
    Matthew Beasley
    British Columbia Cancer Agency, Vancouver, Canada
    Radiat Oncol 3:8. 2008
  3. ncbi Predictors of androgen deprivation therapy efficacy combined with prostatic irradiation: the central role of tumor stage and radiation dose
    Scott Williams
    Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia
    Int J Radiat Oncol Biol Phys 79:724-31. 2011
  4. ncbi Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics
    Cécile Proust-Lima
    INSERM, U897, Epidemiology and Biostatistics Research Center, Bordeaux, France
    Int J Radiat Oncol Biol Phys 79:195-201. 2011
  5. ncbi Radiation therapy of prostate cancer: rationale, pitfalls and the continuing prospect of success forged by medical physics
    S G Williams
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
    Australas Phys Eng Sci Med 32:119-28. 2009
  6. ncbi Does radical treatment have a role in the management of low-risk prostate cancer? The place for brachytherapy and external beam radiotherapy
    Scott G Williams
    Division of Radiation Oncology, Peter MacCallum Cancer Centre, Locked Bag 1 A Beckett St, Melbourne, Vic, 8006, Australia
    World J Urol 26:447-56. 2008
  7. ncbi Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3,264 men: statistical significance without predictive performance
    Scott G Williams
    Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia
    Int J Radiat Oncol Biol Phys 70:1169-75. 2008
  8. ncbi Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer
    Scott G Williams
    Division of Radiation Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 68:24-33. 2007
  9. ncbi A multicenter study demonstrating discordant results from electronic prostate-specific antigen biochemical failure calculation systems
    Scott G Williams
    Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia
    Int J Radiat Oncol Biol Phys 65:1494-500. 2006
  10. ncbi An international multicenter study evaluating the impact of an alternative biochemical failure definition on the judgment of prostate cancer risk
    Scott G Williams
    Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 65:351-7. 2006

Collaborators

Detail Information

Publications20

  1. ncbi Acute toxicity in prostate cancer patients treated with and without image-guided radiotherapy
    Suki Gill
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
    Radiat Oncol 6:145. 2011
    ..We report on toxicity symptoms experienced during radiotherapy treatment, with and without IGRT in prostate cancer patients treated radically...
  2. ncbi Expanded risk groups help determine which prostate radiotherapy sub-group may benefit from adjuvant androgen deprivation therapy
    Matthew Beasley
    British Columbia Cancer Agency, Vancouver, Canada
    Radiat Oncol 3:8. 2008
    ....
  3. ncbi Predictors of androgen deprivation therapy efficacy combined with prostatic irradiation: the central role of tumor stage and radiation dose
    Scott Williams
    Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia
    Int J Radiat Oncol Biol Phys 79:724-31. 2011
    ..To evaluate the response of clinically localized prostate cancer to various durations of planned androgen deprivation therapy (ADT) and to investigate subgroups predicting response...
  4. ncbi Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics
    Cécile Proust-Lima
    INSERM, U897, Epidemiology and Biostatistics Research Center, Bordeaux, France
    Int J Radiat Oncol Biol Phys 79:195-201. 2011
    ..To estimate the α/β ratio of prostate cancer treated with external beam radiation only by use of a model of long-term prostate-specific antigen (PSA) dynamics...
  5. ncbi Radiation therapy of prostate cancer: rationale, pitfalls and the continuing prospect of success forged by medical physics
    S G Williams
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
    Australas Phys Eng Sci Med 32:119-28. 2009
    ..Weaknesses in this evidence base are highlighted in relation to areas directly impacted on by the work of medical physics...
  6. ncbi Does radical treatment have a role in the management of low-risk prostate cancer? The place for brachytherapy and external beam radiotherapy
    Scott G Williams
    Division of Radiation Oncology, Peter MacCallum Cancer Centre, Locked Bag 1 A Beckett St, Melbourne, Vic, 8006, Australia
    World J Urol 26:447-56. 2008
    ..This article aims to review data regarding LRPCa and radiotherapy outcomes, and highlight the potential challenges to improve this data in a planned manner...
  7. ncbi Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3,264 men: statistical significance without predictive performance
    Scott G Williams
    Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia
    Int J Radiat Oncol Biol Phys 70:1169-75. 2008
    ..To define and incorporate the impact of the percentage of positive biopsy cores (PPC) into a predictive model of prostate cancer radiotherapy biochemical outcome...
  8. ncbi Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer
    Scott G Williams
    Division of Radiation Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 68:24-33. 2007
    ..To examine the effect of fraction size and total dose of radiation on recurrence of localized prostate cancer...
  9. ncbi A multicenter study demonstrating discordant results from electronic prostate-specific antigen biochemical failure calculation systems
    Scott G Williams
    Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia
    Int J Radiat Oncol Biol Phys 65:1494-500. 2006
    ..To evaluate the interobserver variation of four electronic biochemical failure (bF) calculators using three bF definitions...
  10. ncbi An international multicenter study evaluating the impact of an alternative biochemical failure definition on the judgment of prostate cancer risk
    Scott G Williams
    Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 65:351-7. 2006
    ..To evaluate the impact of an alternative biochemical failure (bF) definition on the performance of existing plus de novo prognostic models...
  11. ncbi Characterization of the behavior of three definitions of prostate-specific antigen-based biochemical failure in relation to detection and follow-up biases: comparison with the American Society for Therapeutic Radiology and Oncology consensus definition
    Scott G Williams
    Peter MacCallum Cancer Centre, Melbourne, Australia
    Int J Radiat Oncol Biol Phys 64:849-55. 2006
    ..To examine the impact of detection biases on three prostate cancer biochemical failure (bF) definitions in comparison with the existing American Society for Therapeutic Radiology and Oncology Consensus Definition (ACD)...
  12. ncbi High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial
    Maroie Barkati
    Division of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Australia
    Int J Radiat Oncol Biol Phys 82:1889-96. 2012
    ..High-dose-rate (HDR) brachytherapy as a monotherapy is appealing, but its use is still investigational. A Phase II trial was undertaken to explore the value of such treatment in low-to-intermediate risk prostate cancer...
  13. ncbi What defines intermediate-risk prostate cancer? Variability in published prognostic models
    Scott G Williams
    William Buckland Radiotherapy Centre, The Alfred Hospital, Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 58:11-8. 2004
    ..To assess the efficacy of a variety of prognostic models in the definition of intermediate-risk prostate cancer and to compare them to our own empiric model...
  14. ncbi Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer
    Scott G Williams
    William Buckland Radiotherapy Centre and Monash University, Melbourne, Australia
    Int J Radiat Oncol Biol Phys 60:1082-7. 2004
    ..To assess the impact of pretreatment prognostic factors plus subsequent biochemical failure on overall survival after radiotherapy for prostate cancer...
  15. ncbi Ambiguities within the ASTRO consensus definition of biochemical failure: never assume all is equal
    Scott G Williams
    William Buckland Radiotherapy Centre, The Alfred Hospital, Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 58:1083-92. 2004
    ..To quantitate the impact of a number of variables within the American Society of Therapeutic Radiology and Oncology consensus definition (ACD) of biochemical failure (bF) for prostate cancer...
  16. ncbi Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy
    Scott G Williams
    Department of Radiation Oncology, William Buckland Radiotherapy Centre, The Alfred Hospital, Commercial Road, Melbourne, Vic. 3004, Australia
    Radiother Oncol 73:33-8. 2004
    ....
  17. ncbi Urethral stricture following high dose rate brachytherapy for prostate cancer
    Lisa Sullivan
    Division of Radiation Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Australia
    Radiother Oncol 91:232-6. 2009
    ..To evaluate the incidence, timing, nature and outcome of urethral strictures following high dose rate brachytherapy (HDRB) for prostate carcinoma...
  18. ncbi In patients experiencing biochemical failure after radiotherapy, pretreatment risk group and PSA velocity predict differences in overall survival and biochemical failure-free interval
    Daniel E Soto
    Department of Radiation Oncology, University of Michigan, 1500 E Medical Center Drive, Ann Arbor, MI 48109, USA
    Int J Radiat Oncol Biol Phys 71:1295-301. 2008
    ..To characterize the demographics and survival outcomes of localized prostate cancer patients who developed biochemical failure (BF) according to a prostate-specific antigen (PSA) nadir plus 2 ng/mL...
  19. ncbi A prospective dose escalation trial of high-dose-rate brachytherapy boost for prostate cancer: Evidence of hypofractionation efficacy?
    Johann I Tang
    Department of Radiation Oncology, The Cancer Institute, National University Hospital, Singapore
    Brachytherapy 5:256-61. 2006
    ..The study aimed to evaluate mature outcomes of a Phase I/II high-dose-rate brachytherapy (HDRB) boost protocol...
  20. ncbi In regards to Thames et al.: increasing external beam dose for T1-T2 prostate cancer: effect on risk groups. (Int J Radiat Oncol Biol Phys 2006;65:975-981)
    Tom Pickles
    Int J Radiat Oncol Biol Phys 67:318-9; author reply 319. 2007